PP
ATRA icon

PDT Partners’s Atara Biotherapeutics ATRA Stock Holding History

PDT Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,481
Closed -$344K – 951
2022
Q1 		$344K Sell
1,481
-3,255
-69% -$1.04M 0.03% 677
2021
Q4 		$1.87M Buy
4,736
+788
+20% +$332K 0.14% 244
2021
Q3 		$1.77M Buy
3,948
+38
+1% +$13.6K 0.13% 262
2021
Q2 		$1.52M Sell
3,910
-1,838
-32% -$656K 0.1% 301
2021
Q1 		$2.06M Buy
5,748
+1,010
+21% +$446K 0.15% 264
2020
Q4 		$2.33M Sell
4,738
-378
-7% -$174K 0.16% 233
2020
Q3 		$1.66M Sell
5,116
-1,020
-17% -$347K 0.11% 236
2020
Q2 		$2.23M Buy
6,136
+1,828
+42% +$462K 0.15% 200
2020
Q1 		$916K Buy
4,308
+235
+6% +$74.6K 0.07% 238
2019
Q4 		$1.68M Buy
4,073
+2,773
+213% +$956K 0.1% 208
2019
Q3 		$459K Buy
+1,300
New +$485K 0.03% 346

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

PDT Partners's ATRA Position: Q2 2022 in Review

PDT Partners sold out of Atara Biotherapeutics (ATRA) in Q2 2022, closing a stake of 1,481 shares — an estimated $344K sold.

PDT Partners first reported a position in ATRA in Q3 2019 and held it in 11 quarters. The position peaked at $2.33M in Q4 2020. 134 funds tracked by Wall St. Rank hold ATRA as of Q2 2022.

  • PDT Partners reported no remaining Atara Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • PDT Partners sold 1,481 Atara Biotherapeutics shares in Q2 2022, an estimated $344K.
  • PDT Partners first reported a position in Atara Biotherapeutics in Q3 2019 and held it in 11 quarters.
  • PDT Partners's Atara Biotherapeutics position peaked at $2.33M in Q4 2020.
  • 134 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.